Przegląd Menopauzalny

Full text

2/2026 vol. 25
Review paper

Modern methods of treating vaginal dryness and atrophy

Anton Osnytskyy 1
,
Daria Furman 1
,
Kinga Bukała 1
,
Kamil Rutkowski 1
,
Beata Mroczkowska 1
,
Bartosz Kulig 1
,
Krzysztof Szyłło 1
,
Tomasz Szaflik 1

  1. Department of Gynaecology, Oncological Gynaecology and Treatment of Endometriosis, Polish Mother’s Memorial Hospital Research Institute, Lodz, Poland

Menopause Rev 2026; 25(2): 116-122

DOI: https://doi.org/10.5114/pm.2026.164975
Data publikacji online: 2026/09/25
Article file
Modern methods.pdf
  1. Waetjen LE, Crawford SL, Chang PY, Reed BD, Hess R, Avis NE, et al. Study of women's health across the nation (SWAN). Factors associated with developing vaginal dryness symptoms in women transitioning through menopause: a longitudinal study. Menopause 2018; 25: 1094-1104.
  2. Mark JKK, Samsudin S, Looi I, Yuen KH. Vaginal dryness: a review of current understanding and management strategies. Climacteric 2024; 27: 236-244.
  3. Le C, Murgia RD, Noell C, Weiss M, Weiss R. Female genitourinary treatments in aesthetics. Clin Dermatol 2022; 40: 259-264.
  4. Sarmento ACA, Costa APF, Lírio J, Eleutério J Jr, Baptista PV, Gonçalves AK. Efficacy of hormonal and nonhormonal approaches to vaginal atrophy and sexual dysfunctions in postmenopausal women: a systematic review. Rev Bras Ginecol Obstet 2022; 44: 986-994.
  5. González Isaza P, Jaguszewska K, Cardona JL, Lukaszuk M. Long-term effect of thermoablative fractional CO2 laser treatment as a novel approach to urinary incontinence management in women with genitourinary syndrome of menopause. Int Urogynecol J 2018; 29: 211-215.
  6. Karcher C, Sadick N. Vaginal rejuvenation using energy-based devices.Int J Womens Dermatol 2016; 2: 85-88.
  7. Tarabini F, Rozemberg L, Zapata-Sudo G, Braz A. A novel hyaluronic acid filling technique for restoring volume of the labia majora. Cureus 2023; 15: e45728.
  8. Islam RM, Bond M, Ghalebeigi A, Wang Y, Walker-Bone K, Davis SR. Prevalence and severity of symptoms across the menopause transition: cross-sectional findings from the Australian women’s midlife years (AMY) study. Lancet Diabetes Endocrinol 2025; 13: 765-776.
  9. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010; 85: 87-94.
  10. Hill DA, Taylor CA. Dyspareunia in women. Am Fam Physician 2021; 103: 597-604.
  11. Santoro N. Perimenopause: from research to practice. J Women Health (Larchmt) 2016; 25: 332-339.
  12. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010; 85: 87-94.
  13. Santoro N, Epperson CN, Mathews SB. Menopausal symptoms and their management. Endocrinol Metabol Clin N Am 2015; 44: 497-515.
  14. Loprinzi CL, Abu-Rustum SS, Ingle JN. Vulvovaginal atrophy. Mayo Clin Proc 2013; 88: 621-631.
  15. Santen RJ, Stuenkel CA, Davis SR, Pinkerton JV, Gompel A, Lumsden MA. Managing menopausal symptoms and associated clinical issues in breast cancer survivors. J Clin Endocrinol Metab 2017; 102: 3647-3661.
  16. Lubián López DM. Management of genitourinary syndrome of menopause in breast cancer survivors: an update. World J Clin Oncol 2022; 13: 71-100.
  17. Salari N, Heidarian P, Jalili F, Babajani F, Shohaimi S, Nasirian M, et al. The sexual dysfunction in women with thyroid disorders: a meta-analysis. BMC Endocr Disord 2024; 24: 279.
  18. Pastoor H, Timman R, de Klerk C, Bramer WM, Laan ET, Laven JS. Sexual function in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biomed Online 2018; 37: 750-760.
  19. Nagarajan DR, Mani Jacob D, Munir Mufti M, Rajesh S, Dube R. Efficacy of seed cycling as an integrative therapy for premenstrual syndrome and polycystic ovary syndrome in reproductive-aged women: a systematic review. Cureus 2025; 17: e90997.
  20. Yencilek F, Attar R, Erol B, Narin R, Aydın H, Karateke A, et al. Factors affecting sexual function in premenopausal age women with type 2 diabetes: a comprehensive study. Fertil Steril 2010; 94: 1840-1843.
  21. Lorenz T, Rullo J, Faubion S. Antidepressant-induced female sexual dysfunction. Mayo Clin Proc 2016; 91: 1280-1286.
  22. Smith NK, Jozkowski KN, Sanders SA. Hormonal contraception and female pain, orgasm and sexual pleasure. J Sex Med 2014; 11: 462-470.
  23. Casado-Espada NM, de Alarcón R, de la Iglesia-Larrad JI, Bote-Bonaechea B, Montejo ÁL. Hormonal contraceptives, female sexual dysfunction, and managing strategies: a review. J Clin Med 2019; 8: 908.
  24. Gilbert NM, Lewis WG, Lewis AL. Clinical features of bacterial vaginosis in a murine model of vaginal infection with Gardnerella vaginalis. PLoS One 2013; 8: e59539.
  25. Gaziano R, Sabbatini S, Monari C. The Interplay between Candida albicans, vaginal mucosa, host immunity and resident microbiota in health and disease: an overview and future perspectives. Microorganisms 2023 M; 11: 1211.
  26. Windham GC, Mitchell P, Anderson M, Lasley BL. Cigarette smoking and effects on hormone function in premenopausal women. Environ Health Perspect 2005; 113: 1285-1290.
  27. Battaglia C, Battaglia B, Mancini F, Persico N, Nappi RE, Paradisi R, et al. Cigarette smoking decreases the genital vascularization in young healthy, eumenorrheic women. J Sex Med 2011; 8: 1717-1725.
  28. Marchesoni D, Mozzanega B, De Sandre P, Romagnolo C, Gambari PF, Maggino T. Gynaecological aspects of primary Sjogren’s syndrome. Eur J Obstet Gynecol Reprod Biol 1995; 63: 49-53.
  29. Farenhorst CA, de Wolff L, Arends S, van Nimwegen JF, Kroese FGM, Verstappen GM, et al. Clinical determinants of vaginal dryness in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol 2021; 39: 73-79.
  30. Hsu CW, Lee JT, Koo M. Sexual dysfunction in women with primary Sjögren’s syndrome: a systematic review and meta-analysis. Sex Med Rev 2024; 12: 299-306.
  31. Costa APF, Sarmento ACA, Vieira-Baptista P, Eleutério J Jr, Cobucci RN, Gonçalves AK. Hormonal approach for postmenopausal vulvovaginal atrophy. Front Reprod Health 2021; 3: 783247.
  32. Angelou K, Grigoriadis T, Diakosavvas M, Zacharakis D, Athanasiou S. The genitourinary syndrome of menopause: an overview of the recent data. Cureus 2020; 12: e7586.
  33. Nyback S, Poromaa IS, Lindman H, Hirschberg AL, Kallner HK, Wikman A, et al. Vaginal tamoxifen – a potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen. Eur J Cancer 2026; 236: 116261
  34. Maffei S, Formica A, Corsini D, Franchini M. Long-term effects of ospemifene on densitometric and bone metabolism biomarkers in postmenopausal women reporting vulvar and vaginal atrophy (VVA). BMC Womens Health 2026; 26: 296.
  35. Bensmail H, Marchand Lamiraud F, Martin C, Pelckmans S, Cha’ban F, Frisch AS, et al. Hyaluronic acid injection to treat symptoms of vulvovaginal atrophy and improve sexual function in postmenopausal women a 52-week long-term follow-up. Maturitas 2025; 201: 108687.
  36. Kolczewski P, Parafiniuk M, Zawodny P, Haddad R, Nalewczyńska A, Kola- sa AK, et al. Hyaluronic acid and radiofrequency in patients with urogenital atrophy and vaginal laxity. Pharmaceuticals (Basel) 2022; 15: 1571.
  37. Dahab M, Ramasamy K, Ibrahim B. Hyaluronic acid for vaginal health and quality of life in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Int J Gynecol Obstet 2026; 174: 643-654.
  38. Sarmento ACA, Fernandes FS, Maia RR, de Araújo Santos Camargoa JD, de Oliveira Crispimb JC, et al. Microablative fractional radiofrequency for sexual dysfunction and vaginal trophism: a randomized clinical trial. Clinics (Sao Paulo) 2023; 78: 100293.
  39. Kolczewski P, Parafiniuk M, Zawodny P, Haddad R, Nalewczyńska A, Kolasa AK, et al. Hyaluronic acid and radiofrequency in patients with urogenital atrophy and vaginal laxity. Pharmaceuticals (Basel) 2022; 15: 1571.
  40. Palucci M, Barba M, Cola A, Costa C, De Vicari D, Frigerio M. Efficacy of non-invasive monopolar radiofrequency for treating genitourinary syndrome of menopause: a prospective pilot study. Clin Pract 2025; 15: 155.
  41. Benini V, Ruffolo AF, Casiraghi A, Degliuomini RS, Frigerio M, Braga A, et al. New innovations for the treatment of vulvovaginal atrophy: an up-to-date review. Medicina (Kaunas) 2022; 58: 770.
  42. Okui N. Vaginal laser treatment for the genitourinary syndrome of menopause in breast cancer survivors: a narrative review. Cureus 2023; 15: e45495.
  43. Kolczewski P, Kozłowski M, Cymbaluk-Płoska A. Micro-focused ultrasound therapy in patients with urogenital atrophy and vaginal laxity. J Clin Med 2022; 11: 6980.
  44. Fabi SG. Noninvasive skin tightening: focus on new ultrasound techniques. Clin Cosmet Investig Dermatol 2015; 8: 47-52.
  45. Elias JA, Galich M, Corin G, Garcia PN, Sivo V, Nestor D, et al. Management of vaginal atrophy, vaginal hyperlaxity and stress urinary incontinence with intravaginal high-intensity focused ultrasound (HIFU). Int J Obstet Gynaecol Res IJOGR 2019; 6: 735-765.
  46. Önder Dirican A, Ceran M.U, Kahraman O, Sönmez MG. High-intensity focused ultrasound (HIFU) for the treatment of female urinary incontinence: a retrospective analysis. Medicine (Baltimore) 2024; 103: e39940.
  47. Sarmento ACA, Kamilos MF, Costa APF, Vieira-Baptista P, Eleutério J Jr, Gonçalves AK. Use of moisturizers and lubricants for vulvovaginal atrophy. Front Reprod Health 2021; 3: 781353.
  48. Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric 2016; 19: 151-61.
  49. Waghe T, Acharya N, Karnik M, Mohammad S, Patel NA, Gemnani R. Role of platelet-rich plasma in genitourinary syndrome of menopause. Cureus 2024; 16: e53316.
  50. Hamid ASA, AbdAllah AM, Fathi HM, Eldin AMB, El Hadi RMMA. Value of injection of plasma-rich platelets in the vaginal mucosa in cases with vulvovaginal atrophy: a prospective double-blinded randomized controlled study. BMC Womens Health 2025; 25: 576.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Coverage in
Indexed in
pubmed
Integrated with
plagiat pl
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications